Atlas Trials

Abivax S.A.

23 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Abivax S.A.

RecordFirmDate
Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation (NCT07453784)Abivax S.A.2026-03-03
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease (NCT06456593)Abivax S.A.2024-10-30
ABTECT - Maintenance (NCT05535946)Abivax S.A.2023-01-16
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 (NCT05507216)Abivax S.A.2022-12-21
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 (NCT05507203)Abivax S.A.2022-10-10
Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients (NCT03905109)Abivax S.A.2022-09-19
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis (NCT05177835)Abivax S.A.2021-12-03
Safety and Pharmacokinetics Study in Healthy Japanese Volunteers (NCT05032560)Abivax S.A.2021-09-27
Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464 (NCT05121714)Abivax S.A.2020-12-17
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 (NCT04393038)Abivax S.A.2020-07-01
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis (NCT04023396)Abivax S.A.2020-01-13
Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis (NCT04049448)Abivax S.A.2019-10-25
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma (NCT03897543)Abivax S.A.2019-08-30
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis (NCT03760003)Abivax S.A.2019-08-13
Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis (NCT03813199)Abivax S.A.2019-07-04
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis (NCT03368118)Abivax S.A.2018-01-20
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis (NCT03093259)Abivax S.A.2017-11-16

Track Abivax S.A. automatically

Every clearance here is in the API, with alerts when new ones post.